Merck KGaA's MS Drug Mavenclad May Defy Doubters
The German group's oral treatment is late coming to the market but a key opinion leader believes that it will change the way multiple sclerosis is treated.
You may also be interested in...
Merck will develop Chord’s lead drug candidate, an oral version of cladribine, for the treatment of neuromyelitis optica spectrum disorders and generalized myasthenia gravis.
German Merck tells Scrip Mavenclad's long spell in the regulatory 'wilderness' allowed it to amass deep safety and efficacy data that should help the oral MS drug's commercial prospects.
CEO Stefan Oschmann is sticking to his previous forecast of annual peak sales of €500-700m for Mavenclad, excluding the US, and Merck has high hopes for another MS treatment, the BTK inhibitor evobrutinib, following promising Phase IIb data.